Apr. 10 at 3:01 AM
$NAUT The market gonna do what the market do but just FYI, there were days while
$NAUT's product was in the R&D phase that shares were selling in the
$4+ range and investors were posting, "When is the instrument gonna be built?" Well, the instrument is available and adopted by at least two prestigious research organizations via
$NAUT's Early Access Program (EAP) and shares are selling for
$3+. Shares are a bargain at this price. Much upside in the near term as additional assays are validated and instruments are acquired via the EAP.
